Literature DB >> 5141410

A 10 years' study of kala-azar in Tharaka (Meru district, Kenya). II. Relapses.

D J Wijers.   

Abstract

Mesh：

Year:  1971        PMID： 5141410

Source DB:  PubMed          Journal:  East Afr Med J        ISSN： 0012-835X


× No keyword cloud information.
  6 in total

1.  Use of in vitro method to assess different brands of anti-leishmanial drugs.

Authors:  S K Arora; R Sinha; S Sehgal
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

2.  Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis.

Authors:  J L Avila; M Rojas; L García
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

3.  Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.

Authors:  Abdolvahab Alborzi; Gholamreza Pouladfar; Armin Attar; Fatemeh Falahi; Zahra Jafarpour; Abdollah Karimi; Mohammad Rahim Kadivar
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

4.  Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion.

Authors:  Mireille Basselin; Hubert Denise; Graham H Coombs; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis.

Authors:  M A Jaser; A el-Yazigi; S L Croft
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

6.  Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis.

Authors:  A Schriefer; A Barral; E M Carvalho; M Barral-Netto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.